Site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.


Long-term prevention. Long-term support.

TAKHZYRO has an established safety profile and effectiveness in patients 2 years of age and older.1,2

This was demonstrated in a 6.5-month study and a 2.5-year open-label extension study in patients ≥12 years of age and in a 12-month open-label study in patients 2 to <12 years of age.1-3

Takeda is here to support your patient's treatment journey for the long term, with 12+ years of experience treating and providing product support services for people with HAE.


Cultivating Lifelong Relationships

HCPs can play a big role in keeping patients engaged throughout their entire treatment journey: discussing positive outcomes, working through breakthrough attacks, celebrating milestones, staying committed, and more. Watch as a real TAKHZYRO patient speaks with an HAE expert about all the ways they can stay connected throughout their treatment journey.

View Transcript

Dr William Lumry: ... exactly.

Pam: You never know what you're going to be doing. Oh, hi.

Dr William Lumry: Thank you, Kevin.

Pam: It looks great, thank you.

Dr William Lumry: Appreciate it. Pam, it's great to see you. The last time we talked, you were planning a family party, I think, right?

Pam: We did. Everyone had a great time and I wasn't worried about experiencing an HAE attack.

Dr William Lumry: That's great to hear. I remember you sharing stories about avoiding certain events because of concern about having an attack, and how the unpredictability of attacks impacted you.

Pam: I think those conversations really helped you understand what I was going through and helped me get on the right preventive treatment.

Dr William Lumry: I've heard from many of my patients that preventive therapy has helped them. I'm glad it's worked that way for you. How are your daughters doing?

Pam: They're wonderful. One just came back from a trip abroad. Thanks for preparing us in case she had an attack while she was gone.

Dr William Lumry: Of course, I'm always happy to help patients plan ahead to reduce the possibility of an HAE attack.

Pam: Well, thanks to you, the timing worked out, so she was between doses during her vacation and she didn't need to pack her preventive medication, so she had a really great time.

Dr William Lumry: Good for her.

Pam: I'm just so grateful that my girls and I have someone like you who's been a part of our lives for over 10 years and who really knows us and understands what we're going through with our HAE.

Dr William Lumry: That's why we do what we do. You know, I'm glad I was able to prescribe the three of you TAKHZYRO and that it's been effective for you. You know, HAE attacks affect every patient differently, so each patient needs to be treated uniquely. When I talk about treatment options, we discuss their expectations regarding efficacy, preferences for the route of administration, potential side effects, safety information, the approval process, and so on and so on. That helps them decide which treatment might be best for them.

Pam: There is a lot to consider.

Dr William Lumry: There really is. And on top of that, as you know, HAE can change over time. It can become more or less severe, as a result, a patient's needs may change too, so healthcare providers need to keep checking in and continuing to ask the right questions.

Pam: You were the first physician, after years of searching, who listened to me instead of just talking to me, and you asked how I was really feeling, what was going on in my life, what I wanted to accomplish, how my HAE affected me, and how I felt between attacks.

Dr William Lumry: And to your credit, you answered all the questions. You know, not all patients are comfortable talking about their lives in that way, but it helps paint a fuller picture so together we can figure out the best way to manage their HAE attacks.

Pam: It's been a long journey for me to feel like my HAE doesn't define me.

Dr William Lumry: And that journey you talk about is ongoing, Pam. It doesn't end once you're on a preventive treatment you're happy with. We discuss updates on how you're feeling, if anything has changed with your HAE, and if the treatment is still meeting your goals.

Pam: I can't begin to tell you how much that means to me and my family.

Dr William Lumry: I want my patients to be engaged every step of the way and empowered to feel like they have choices, and I want them to trust that our office will be true partners with them throughout their journey.

Pam: I totally feel that and I know my daughters do too.

Dr William Lumry: That's great. And TAKHZYRO offers patients every-two-week dosing with the option of going to every four weeks if things are well controlled, which I hope has helped as well.

Pam: TAKHZYRO has made a difference in our lives by reducing HAE attacks. I have to tell you, I'm so relieved that there's something available that has been proven to help reduce the frequency of those attacks.

Dr William Lumry: I am too, and I appreciate how you keep me informed about your progress, not just with TAKHZYRO, but with everything going on in your life. It helps us make sure we can keep up with your routine.

Pam: Well, you've made yourself so available to me and my family over the years, and you've gone above and beyond to take care of us. Thank you for everything that you continue to do for those of us with HAE.

Dr William Lumry: Thank you, Pam. I'm glad we got a chance to visit today.

Narrator: TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.
Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10%) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; dizziness; diarrhea; and myalgia. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <2 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-877-TAKEDA-7 (1-877-825-3327), or FDA at 1-800-FDA-1088 or

Please see full Prescribing Information at


Remind your patients
why they started

Continue to check in—reinforcing the impact effective prevention has had on their lives and their progress since starting TAKHZYRO.

HAE attacks can be unpredictable, debilitating, and even life-threatening. Your patient’s adherence to their HAE preventive treatment plan is the best way to help stay ahead of future attacks. Their next HAE attack may be nothing like their last, and it won’t be their last. That’s why it’s so important you remind them to keep taking TAKHZYRO as prescribed so they can continue to see improved outcomes and reimagine their life with HAE.2,4-6

Considerations for the next check-in with
your patient

HAE is a lifelong condition, and it's important to set specific goals for therapy. Choosing TAKHZYRO may allow patients to achieve effective prevention of attacks for periods of time when treating this unpredictable disease.1,2 Important metrics to track as they progress toward their goals are:

  • Your patient’s HAE attacks. What were their frequency and severity before preventive treatment and now?
  • On-demand medication. How often has your patient used it since taking TAKHZYRO?
  • Check for proper adherence. Is your patient taking TAKHZYRO exactly as prescribed and sticking with their dosing schedule?
Think about your patient’s overall HAE management plan

You and your patient decided together to add TAKHZYRO as a preventive treatment to their management plan to fit their needs. These needs can change over time, so consider these other areas recommended by the HAEA as you revisit their plan5:

  • Any other health issues they may have
  • The benefit of keeping a symptom and treatment tracker for review
Setting treatment goals with your patient

A treatment tracker is a great tool that can help you and your patient see how their management plan is working. It can also help to identify triggers so you can work with your patient on how to avoid them. Triggers can include5,7:

  • Stress
  • Hormonal fluctuations
  • Exhaustion
  • Physical pressure
Continue to check in with your patients even if they have been taking TAKHZYRO for 6 months or longer. TAKHZYRO offers flexible dosing to meet patients' needs.1
OnePath® logo.

Personalized product support for patients every step of the way

Remind patients that OnePath® helps people who have been prescribed TAKHZYRO per the approved indication get access to their medication.

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2023. 2. Banerji A, Bernstein JA, Johnston DT, et al; HELP OLE Investigators. Allergy. 2022;77(3):979-990. doi:10.1111/all.15011 3. Data on file, TAK743-301, Takeda Pharmaceuticals USA, Inc. 4. Wang Y, Marier JF, Kassir N, Chang C, Martin P. Clin Transl Sci. 2020;13(6):1208-1216. doi:10.1111/cts.12806 5. Busse PJ, Christiansen SC, Riedl MA, et al. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3 doi:10.1016/j.jaip.2020.08.046 6.. Banerji A. Ann Allergy Asthma Immunol. 2013;111(5):329- 336. doi:10.1016/.anai.2013.08.019 7. Craig J, Banerji A, Riedl MA, et al. Allergy Asthma Proc. 2021;42(3):S11-S16. doi:10.2500/aap.2021.42.210029